ENDP - Earnings call transcript Q2 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Thank you for standing by, and welcome to the Second Quarter 2021 Endo International plc Earnings Conference Call. [Operator Instructions]. I'll now hand the call over to Laure Park, Senior Vice President, Investor Relations and Corporate Affairs. Please go ahead.

Laure Park

Thank you, Michelle. you financial us results. thank second discuss and XXXX quarter morning, for to joining our Good

Vice and Joining Coleman, Operations. of Executive President on and and me today's CEO Endo; call Mark Global Barry, President, Patrick are Blaise President Commercial CFO; Bradley,

have the to today's by Investors to endo.com. would that slide section webcast, materials are remind presentation as like any made as at management well other a forward-looking you posted prepared and We accompany presentation covered applicable and Litigation risks and online to are statements that and the U.S. in Act Reform U.S. securities Securities changes, our in Canadian under Private Canadian the filings. press of XXXX in release and the are the uncertainties described laws and I securities subject

Blaise. of financial the like the States financial most we principles In our be including turn Endo's reasons that X-K financial reconciliation review financial Form to in course to non-GAAP not to call, encouraged now issued noted non-GAAP on are United in that Blaise? accounting different Endo's measures accordance furnished earnings other non-GAAP with measures of to to earnings current measures the the yesterday, GAAP refer are for and release the measures report release in contained with used may are presentation. directly I'd press The by those prepared comparable its the and financial companies. call otherwise therein. SEC may measures Investors for non-GAAP in over from accepted addition, generally during unless

Blaise Coleman

thank and everyone, for morning, us. Good joining Laure. you, Thank you

the across quarter. our financial are performance sequential volume of year strong Based XXXX our our quarter our we full financial including the each We growth double-digit strategic performance, our solid in continued saw XIAFLEX. report Pharmaceuticals segment, priorities driven continued guidance. and the to performance on raising low pleased progress in strength by are of revenue segments, percentage growth of second Branded end better-than-expected against second during We

our Turning to we which Slide X. guide all Last year work introduced we our as at that to transform company. time, strategic priorities, we this do

many XIAFLEX pursue on and we commercial progress continued our manufacturing strategic expand including launch we sale business external our growth strong for portfolio, the Chestnut internal volume a sustainable published through to of execution of of our investments, in second we initiatives, focused we benefit second force successfully priorities. York. of Ridge, areas and effective opportunities plan, In stakeholders. across announced our made to May development and annual our how all on advance that deliver our pipeline initiatives continued to In support progress continued the our progress enhance practices drive of core transformation in core be ambition During reporting our quarter, we and our ESG reinvent continued adopt good, recently actively In business report more our growth. grow across product work, our of all facility our in in X New

quarter. of for snapshot revenues and a our EBITDA Slide and is to Moving segment our this adjusted the X, consolidated

in favorable portfolio our Second increase anticipated from by adjusted prior million consolidated Reported was operating of mainly EBITDA compared Pharmaceuticals by decreases Generic was to offset primarily was increased and by X% and quarter This the year. mix changes segment, $XXX Injectable revenues million and partially expenses. revenues adjusted due second quarter compared X% partially to an revenues increased Sterile increase product offset segments. higher to increase increased Specialty of in to prior year. due the $XXX by Products in Pharmaceuticals This from our revenues Branded of

expenses mainly our the Second expectations previously year. due to across of better-than-expected the adjusted to of of to communicated segments all our EBITDA exceeded due performance operating rephasing quarter half revenues consolidated XXXX the and and expenses adjusted second lower

Turning X. to Slide

to in activity revenues in to compound patient annual volume by execution. by grown On commercial compared the growth XX% the quarter to the Pharmaceuticals increased an XXXX. segment at of have the the coupled XX%. an increase XXX% year, compared a of and prior second visits, and office an XIAFLEX physician continued Branded XIAFLEX driven driven in increased of sales strong over revenues with are year. same XXXX, our period result the to revenues in Specialty by quarter sequential prior performance from net XIAFLEX first These quarter grew increases Compared Second rate compared basis, approximately Products of portfolio. XX% XX%, impressive our increase office

As this strategy additional coupled invest the demand in that earlier investments improve through ongoing half includes to promotion and second strategy. the XIAFLEX campaigns in with to we commercial growth year we part education seek we rates, opportunity options, diagnosis commercial as overall of continuing marketing to and direct-to-consumer awareness patient of to condition empower the overall treatment year, training. nonsurgical increasing patients discussed Based expanded strong awareness enhance the planning are on our in are physician and

and a are activation XIAFLEX. the strategy unlock we further Peyronie's introduce branded Specifically, for DTC a will enable believe indication. consumer further to diagnosis, demand approach branded We planning treatment for

competitor second guidance reflected and of name, investments recovery year the primarily are in continued in the prior driven from who XX% patient the as receive revenues in product so stronger-than-expected by full grew compared well LA by will product's to request Mark shortage. resulting majority the consumers, year, by pandemic, as demand from awareness far quarter a the expanded treatment. experience These discuss Our that financial presentation. our later additional SUPPRELIN XIAFLEX demonstrates

of a quarter months our quarter second We by are first the to declined proud patients XXXX. and XXXX the provide with precocious that of are providers care their Revenues solution and delivers volume Sterile puberty duration. Injectables compared half in by pleased XX growth of the to from health X% central the segment and

quarter in toward expectations a anticipate of decrease did declined. hospitalizations revenues year, full prior in COVID-XX-related anticipated quarter. volume the volumes the XXXX. half exceed levels compared the pre-COVID-XX as by VASOSTRICT year, continued driven revenues However, our in decline VASOSTRICT by assumptions a second for revenue to declined On the X%

Slide to the January year. Pharmaceuticals to decreased The segment the revenues this Moving quarter due our prior to decrease in of lubiprostone X, XX% of the compared This authorized decline anticipated partially Amitiza impact by primarily was of offset launch the successful competitive year. by second prior in events. Generic from the generic of capsules, was

events, revenues Second generic to our to due better-than-expected with Pharmaceuticals expectations anticipated quarter Generic brand the segment certain in mainly competitive coupled lubiprostone exceeded delay conversion.

quarter were the for second revenues International quarter XXXX Finally, revenues. comparable Pharmaceuticals to segment second the

Slide to X. Turning

medical launch date in community who are While and our we positive are from our still feedback with early QWO, have pleased both women of the progress receiving the and aesthetics to we a QWO. QWO, been being recently that which patients showed a the treated clinicians and majority with treated patients market completed survey We professionals and with early of care of health are strong increasing results boost and the in satisfied to patient approximately largely confidence, other of treating the satisfied involve overall would among colleague. Survey others. patients would XX% and a treatment reported the suggest rate a XX% positively the factors. treatment with full fellow to also recommend recommend physicians results. of treatment that After with Approximately QWO experience QWO treatment, the feeling the completing being experienced

placements, marketplace. to XXX enthusiasm had in billion media over media feature brand placements. XX Year-to-date, QWO stories and broadcast consumer planning awareness continues Our PR generate XX had has unique media the X.X generated impressions, and and

to continues QWO beauty consumer Additionally, be with recognized awards.

received home interested to the brought Skin the aesthetics XXXX we treating launched QWO with Beauty breakthrough website consumers New Award X. and to match beauty growing has been recently recently beauty the our complement A Award, practices. Specialist on far, awards So consumer Shape a awarded Find award, To increasing to feature of XXXX Cosmopolitan QWO awareness, number medical

purchase of with planned rates. are our terms utilization launch In on we execution, onboarding, our and account target

a outcomes satisfaction. be to Our supporting patient their focus positive overall aimed integrate and consumer practices effort launch approach an at successfully progressive to practices continues support into and deliberate QWO and in to

focused with are to and durability. dosing, ongoing patient in data-generation our Slide Moving well strategies. X on and studies and these publication Starting studies technique injection analysis clinical to our populations and presentation our on studies responses rollover discussing plans from QWO, pipeline. as key remain Results as branded target

make XIAFLEX Medical Meeting We e-poster treatment at of on Phase the Last safety the for Annual American results in nonsurgical XIAFLEX programs. on to Association Podiatric week, development I presented tolerability plantar an continued and progress we our held the fibromatosis. as Denver

the year. We are are half II initial these fibromatosis our the of to and with initiation program Phase a study progress second this by of encouraged in plantar excited findings

potential address to the bring who unmet represent fibromatosis IIb end capsulitis, adhesive of are is innovative treatment. and We the terms towards In nonsurgical capsulitis our year. study approaches anticipated to interim for needs opportunities of options seeking believe treatment both to plantar analysis adhesive patients Phase large

support Overall, capsules R&D products. in products more to with sterile more approximately injectable approximately plan Generic Turning year. XXXX, the sterile continue launch to XX segments, of our injectable to evolve lubiprostone and XX continuum consists in ready-to-use our launch that greater of X/X product X, includes the projects pipeline increased than to Across number this capabilities needs we our has which Slide we The of Sterile differentiated introduction XX% the our of of projects. our our manufacturing with to pipeline R&D evolving on of of sterile focus and in Injectables the projects customers. pipeline approximately across R&D addition new products and earlier

continue efforts leverage In injectables therapeutics, in and further development us our existing medical front. on and the on including areas addition to We're we to growth, to medical enhance focused of expand portfolio, capabilities. opportunities business active to, our enable core to organic remain our aesthetics sterile

business and development take deploying have disciplined will approach to to a We capital continue taken opportunities. on

Now discuss guidance. financial the the me our company's to Mark and turn let over further results Mark? financial to call

Mark Bradley

Thank good you, morning, Blaise, and everyone.

higher interest of quarter favorable a the change attributable basis income decrease Tennessee operations second to share product million $XXX expense, partially amounts mix. diluted and $XX increased in not XXXX of from see higher per a second XX, second operations a our results. $XX of million diluted will million so of earlier, GAAP review and revenues $X.XX snapshot basis in First, share settlement consolidated segment offset second of announced was a on comparable quarter on financial a per will and basis the similar in and continuing continuing costs, the loss Blaise the approximately compared or of income quarter again. to On revenues per an $X.XX basis, litigation-related including adjusted on On Slide non-GAAP to was in of share This you by recently $X.XX on or primarily or from diluted GAAP continuing a I covered and in operations basis, was was that the approximately second quarter quarter from XXXX. XXXX XXXX.

increase product Second quarter an mix, favorable offset second a and quarter interest by partially compared the XXXX. increases XXXX results change reflected expenses in revenues in of to expense operating and in

of to Turning segments full expect full year low operations to and XX, performance be on our revenues end net billion, total diluted the between $X.XX better-than-expected second $X.XX year We the financial $X.XX to $X.XX based adjusted be share are be across billion guidance. raising income Slide between quarter, billion now and $X.XX to all our EBITDA continuing adjusted XXXX between XXXX per we of $X.XX. billion and in and from

XX%, tax to adjusted assume $XXX an XX% year XX%. of margin interest effective approximately adjusted XX% Our expense continues rate to an of to of guidance and full gross million XXXX adjusted

of operating revenue XX.X%. adjusted assume be as expenses now percentage a we will However, approximately

offset guidance guidance to hospitalizations not during quarterly the a restrictions While to year our COVID-XX uncertainties, respect broad resurgence by expect total XXXX. to to segment XXXX a $XX the in flat competition in is as expected of to a phasing, relatively continues be of anticipated remainder to on portfolio to With significant the to certain our to are due number Sterile to to expected to segment third declines Branded quarter levels does full of decline continued generic $XX contemplate in XXXX in to Products continued of of million by is second due of different XXXX reinstatement Generic as due remain lower competition. products. expectations demand continued return Established second third segment driven by assume revenues This quarter ranges Injectables lower revenues well we more decline for lower quarter compared Pharmaceuticals year. of COVID-XX-related our million Pharmaceuticals normalized as the or as the growth revenues the quarter XIAFLEX approximately expected VASOSTRICT compared of revenues be volumes

change full adjusted gross quarter expect reflecting of in We in the guidance at the the range, end margin third mix. product low year to the XXXX be

of Additionally, R&D the the which to the to we mid-XX% in of branded increased the is launch a progression a expect adjusted operating year indications, direct-to-consumer segment to the percentage campaign a growth the low of pipeline of in support expenses our for reflects investments quarter branded range, enterprise to revenue Switching and which projects indication. injectable and as be XX, continued this of Peyronie's our third sterile assumptions. our on-market summary includes total revenue XIAFLEX and of full Slide introduction QWO,

compared to $XXX in in notice, will year in ended approximately due million and full you $XXX by partially our a XX Advancing of discussion, XXXX approximately and payments up capital quarter cash Sterile interest was and flow the unrestricted cash well $X.X million for decrease have wrapping primarily working Slide VASOSTRICT. debt-to-adjusted second XXXX the assumptions As to net was X we leverage We was ratio cash in prior the updated and the tax to Injectables and months a net financial from cash segments first decrease This in as EBITDA a billion and Pharmaceuticals, to slightly unrestricted net for flow Pharmaceuticals year. of an Branded increase of decrease for changes of Generic payments refunds. revenue Xx. XIAFLEX as cash offset debt prior with the

in in and for the EBITDA estimate which expenses from an are year settlements, reflects guidance $XXX increase change compared full million announced coupled to our prior XXXX, updating million changes This and the with in offset discussed corresponds increase with we cash expectations million $XXX $XXX cash partially $XXX net between end low primarily adjusted be previously cash increases by capital, Tennessee and between the for unrestricted million. of to to settlement. the flow For payments debt distribution the opioid-related range our working flow approximately of legal recently prior in

turn now me over to back Let call the Blaise? Blaise.

Blaise Coleman

Thanks, Mark.

call our recently our we whole. a regarding Tennessee turning questions the California Okay, as to are over understand and opioid manage matter Laure to in York, prior the litigation trials many ongoing to there New question-and-answer period, our announced and settlement

litigation comment pending, to path so the necessary. to those on constructive a the a the With as With of continue open and includes resolution. California we're sure constructive as proceedings. based kind will associated front. opioid can on of on and say on by it to if be not on no note can there we costs. this and remains you avoiding appreciate, our respect limited can or settlement important of Tennessee, Endo achieved respect liability admission any what and to decision we litigation be going for However, wrongdoing, I'm no to to liability executing litigate we're goal, fault phase that into are both to this be are whole, our It's risk and while assurances With continue respect identifying prepared to enter to that we was to case's trials New York, our resolution

be we opioid address of our priorities us they litigation, our in aspire day-to-day serve. our highly commitment the members our products the helping patients quarter thank their More and our the to portfolio each to strategic we to the and company of remains focused advancing Endo Endo to customers continue business to team our want strong the continued life-enhancing that on into execution, I during execution delivering transform future. and importantly, while for team on all

turn to to our over period. manage Let the me now Laure question-and-answer call Laure?

Laure Park

the first can Operator, [Operator Blaise. please? Instructions]. we question, you, Thank have

Operator

comes from Schott Chris with Our question first JPMorgan.

Christopher Schott

those specifically, early XX% to cited the is I XX% satisfied refine population? the target I the anything take with that there on just further satisfaction that guess, Were you access there in, and I themes any some look was maybe maybe I how I and positioning maybe question rates you guess XX% some guess guess, away then just rate. numbers satisfaction of guess program, weren't about that as of QWO good the my the more but in think rollout do broader about from the just given we you high product? you about is see broadly, clearly aesthetic number, of other you as survey that use think going And markets, forward? that a a I think initial you

Blaise Coleman

those Patrick Yes. I'll for And much Chris, those. you let thank Patrick? questions. very address

Patrick Barry

takeaway for question, early directional think Thanks the the market that, Yes. I the what is research early an on Chris. Again, experience trend. that's

of So early we their of did course engage the therapy. completion with actually relatively those patients after

good in XX% directionally our So other what we for we that really a us. also fact well. generation It is saw of like is the consistent as some data somewhat watermark with

studied at patients Improvement investigator look and trial, and well both scores we If thighs, our XXs. scores Aesthetic which patient into saw in satisfaction Global you XXX buttocks the

we're in outcomes patient a satisfaction. directionally, again, days, patient good on early looking good So the and for focus

so outcomes. what And survey this data where want is in continue generation focus also see, to seeing patient good we're exactly of in is what that's drive terms and we're to seeing to what and our small we market

Operator

next Amsellem question David comes Piper Our from with Sandler.

David Amsellem

not if a ran believe, a VASOSTRICT, looking ready-to-use formulation. I'm PK XXXX, in I on study, So you at mistaken, back

broadly to can lose be any for the mind, you extent you position to with version broadly when about So to to could you liquidity expect market? on in and create it in exclusivity, any you? bring improved do of you that can talk about the And VASOSTRICT issues extensions line then extent just a talk to

Blaise Coleman

you the on thank questions VASO. David, for Great.

to a is like that as launch we've approved VASO identify going premix market. look to What very benefits will whether we value have bottle they product strategically. bring product we management So premix that. of the life to that's we what right where active David, about strategy cycle our believe bring that on a now really can And VASOSTRICT ready-to-use is VASO, customers to bottle, we do the around realize have talked and a

potential terms exclusivity, not around really to of going In speculate of outcomes that. we're launch David, around

stand with And court in Overall, Delaware. feel potential but outcome. right that where of that very outcome that we'll we be But decision of the our ready the now, on good matter for not terms of going liquidity we're that standpoint, the matter. have a terms We is, liquidity our about -- on we front speculate matter. that's regardless in to from is and the go-forward pending VASOSTRICT whatever position in

on that comment decision we're more Delaware So not the have to going until we in trial. much the

Operator

question Ty comes Navann next with from Citi. Our

Navann Thank you

plaintiffs know try are And do can't California, had And timing? to on comment settle? able you on on and idea are I global on any better I on second New you then opioids? generally can a you Do more willing progress introductory York comment potential First, a settlement? on feel that but have you the I towards of have update question you if price. to a QWO, the the

Blaise Coleman

take I'll don't why on Patrick, and the comment opioid question. the you price

Patrick Barry

through a $XXX got per Blaise. And not to Sure, is Yes. an is price $XXX. program have out got We ml X received X price positive we've still early receptivity really and we've price we our then and what in X launched an points commenting the I ml very that, that point. introductory at at vial that would say there. beyond so experience We're We've market.

also in very consumers. a the I vertical. think our price doing it in to swath to marketplace clinicians product to a of that's drive that But a creates accessible wide good it allows new introduce margin, allows a so, us have

to cellulite our first positive points. We've only we really on that's address at a scale really the and received those effective wide price a, wanted feedback an injectable and for, is that's price. so do need treatment what And

Blaise Coleman

identifying in our of resolution. opioids for to of remarks, all continue a in executing constructive best the various work constructive We to type prepared said that towards On parties on it's resolution. stakeholders and the the of we believe as and find interest path question, we

likelihood we when be that timing However, us said, assign this possible outcome or outcome of of might reached. that is a for the as probability very really complex And to not of matter. it's

Operator

comes question next Capital Nachman Markets. Our Gary BMO with from

Gary Nachman

the a or with Dupuytren's forward for you with And of like tailwind surgical to campaign. been EEP. process have upside physicians think just certified this continues at network a with expand upside in coming how And outperform, going one for that getting get How many the pretty next from And optimistic over to less for XIAFLEX it As getting I on Peyronie's the Peyronie's? people much comment the thus point? procedures from will Can the has year? seems you that? more will quick pandemic talk the on started how you're are DTC you you inclined then out. play XXX QWO. Just and And you that trained far? about

Blaise Coleman

on and just a for are our comment Yes. growth We're focused numbers is exactly awareness Gary, some Peyronie's that well. on a driving comment made. a Patrick we both. of move on now, specific big this Thanks, more of that we're training. On Patrick We really product let feel on additional Patrick front progress the that the on comment to provide seen very doing about on XIAFLEX really as get trained date. Gary, quick indication. to is again, we've on many we're strategy Maybe both what going how we've those I'll let good branded But moment. questions. And into right we've color QWO, excited impressive on about and about a indications, at not that really I'll, trial part can in probably and that

Patrick Barry

Sure.

the Let thank question. for me -- you

very start with really growth impressive across indications. XIAFLEX. me really seen both We've Let

the perspective we XXX%. in year. we As across prepared growing excellent a our underlying sequential perspective. versus The saw indication indication largely the from prior about an growth volume demand driven growth grew at And XXX%. Dupuytren's board. really of saw grew was indications comments, Peyronie's over at and XX% revenue are volume from that discussed Both we And

X So versus double-digit quarter in quarter X. volume growth

across to good signs all health really see see. we we strong want So molecule, exactly and really what that the that's

committed We're attribute physician of of increase an the seeing fact terms in an market, plan approach maximization attribute with relates forward to Peyronie's. well. to XIAFLEX our things. are that plans that on As would based our we direct-to-consumer branded I and to that extremely moving the behind would a activities. to resources seeing in It's that pre-COVID it activation activity. right introduce consumer stay level confidence patient to we the in to that executing -- And and are strategy a towards we're continue teams couple have I

have us As condition the get we a and the the that a call action is key for marketplace. they when Peyronie's for of do key that created ask we've for to strong time, that learning XIAFLEX, awareness, created insight XIAFLEX. in And patient does, fact, in indication, majority

to And great and that a treatment for an the for of us, unlock underlying which so campaign, lot further part patients. really going of year opportunity us latter diagnosis exudes will which think the we branded and enable demand, a exciting for confidence into is introduce

it outcomes As Blaise and it their physicians on days, I early helping patient addressed relates practice confidence. it's have Again, integrate QWO, about think and to really that I in the focusing to question. into think

in prepared positive. comments, again, so very very, the And our trends are

you at to well. experience market we Those the If treatment with QWO, the they're that's patients early experience to positive influencers are Endo experience Aesthetics, as those satisfied recommend want look and a satisfied of exactly willing what XX% they're see. had fact that with program, positive and their with

early So our that's and integrated is repeat on utilization. patient practices the deeply outcomes, into focus really days getting the in

Operator

Instructions]. [Operator

Stifel. with Samimy Annabel from comes question next Our

Annabel Samimy

again questions few on QWO. A

as time of coming what the far you've full market, little seeing in patients it's competitive the buzz quite that Have And potential is any then how was Soliton Allergan as a launch are now physicians in heard just with of time. course some soft out had And for the treatment? going you? by introduction for First, acquired for there for to cellulite, changing which there? landscape Aesthetics, XIAFLEX, you on the the be been

imagine already most the have product this of Now who I would adopted. physicians adopt that

So primary more patients to but the population investment in is move your fully the investment dollars penetrated physician you've that your you can and bring in, area? focus what of do feel you the development clearly DTC

Blaise Coleman

on XIAFLEX, as consumer for now Thanks a branded further significant, about Patrick X is still opportunity which going we're and QWO drive Peyronie's a XIAFLEX. there. comment said, one excited activation by into significant quick on Maybe Great. Patrick is, the of the what ways there of on moving disease. to is really And those the questions we're or consumer. said, is just which strategy activation And

can we activate there's as to that treat recognizes says, but further Patrick to and use impact additional existing drive as name, additional that Patrick, also But consumer consumer only demand injectors not new physicians that and going knows only also not today, going of QWO maybe extension but have XIAFLEX. nonsurgical that forward. a so that anything significant by XIAFLEX And on treatment with condition, that's you comment it on and else

Patrick Barry

do so. to Happy Sure.

treatment. Again, physicians the we're are Let a for full but and of it's cycles with full at through a course QWO patients seeing way. question. me positioning start clinical trials, X go and so willing -- the that we're Again, certainly it seeing that physicians course to courses focused seeing early X days, we on position are QWO generally generally successfully we're

Allergan, size relative way that's certainly only the going into and of feel Allergan like on the we we going get the some it market, The enthusiasm acquisition to for time to condition AbbVie validates like a from that that you're As it, at of coming player any look the awareness. to sentiments market relates cellulite. Soliton opportunity, our fuel

to multi-modality thing type -- approach, a see in look for area physicians most the We and a good aesthetic There's us. times treatments. So certainly medical many we multiple that's the injectables. like injectable, think so room an That's Patients has of -- that first the cellulite. I that very are as accepting with positioning positions really to QWO us and only injectable treat for well.

know no operationalize do in injectable an capital practice. also easily that. know that very outlay. We They physicians how to their can There's

vertical there's them, create accessible And and an opportunity a price addressable an so an wide that margin point grab opportunity market. good for to have new a opportunity to to is to a

about As campaign XIAFLEX, again, on we since the talked in we'll focus indication branded there. our to Peyronie's it relates

erectile dysfunction, treating rates high-prescribing really, on treating treatment a XX,XXX rates basis. that daily low. really We about are got urologists that are diagnosis the and men's You've health issues out know there

a demand. again, get huge create opportunity know has into more great an underlying this ask urologists, name, we for And men feel that treatment only a more so with condition been Peyronie's know it XIAFLEX And treatment the and indication treated. also patients and more more we opportunity to to there's to further unlocks funnel. even And the activate that more we opportunity in pour suffering by Peyronie's are get the more condition on not to more -- when like awareness effective. the they There's diagnosis that growth out there silence of -- disease. but men There awareness, is based

that's so campaign branded with in coming day exciting the for And patients future. the an

Operator

There no the back like Blaise to call turn Coleman closing I'd over for to any questions. further remarks. are

Blaise Coleman

you Thank operator. Great. very much,

you, Just we want and this to providing move morning, look to thank everybody updates for Thank forward everybody. as forward. joining we

Operator

This program. concludes the

may You now have a disconnect. Everyone, great day.

Laure Park	SVP, IR & Corporate Affairs
Blaise Coleman	President, CEO & Director
Mark Bradley	EVP & CFO
Patrick Barry	EVP & President, Global Commercial Operations
Christopher Schott	JPMorgan Chase & Co.
David Amsellem	Piper Sandler & Co.
Navann Ty	Citigroup
Gary Nachman	BMO Capital Markets
Annabel Samimy	Stifel, Nicolaus & Company

Endo International (ENDPQ) 7 Aug 212021 Q2 Earnings call transcript